Lipocine Shares Plunge 77% After Trial Miss

Lipocine Inc. shares plunged 77% after its phase‑3 postpartum‑depression drug LPCN 1154 missed the primary endpoint.
The trial of 90 patients showed no statistically significant HAM‑D17 score reduction at hour 60 versus placebo.
Post‑hoc analysis of 54 patients with psychiatric history revealed nominal significance, with placebo‑adjusted differences of –7.2 at hour 12 and –5.3 at day 30.
Lipocine will seek breakthrough and fast‑track designations, preserve capital, and evaluate further development or partnership options.